• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States

    9/8/25 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email
    • ASANA offers a comprehensive, customizable gas permeable portfolio including spherical, aspheric, toric, multifocal, reverse geometry and keratoconic lenses
    • Designed for durability, ASANA lenses maintain shape throughout the day, resist protein buildup, and provide enhanced visual acuity, particularly for patients with complex vision challenges such as astigmatism, keratoconus and post-surgical conditions
    • Eye care professionals using ASANA can benefit from Bausch + Lomb consultant support for lens fittings, fast manufacturing and shipping and a 120-day EZ-Exchange™ Warranty Program offering unlimited lens remakes*

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of ASANA gas permeable (GP) lenses. ASANA offers eye care professionals a versatile, all-in-one comprehensive GP portfolio, featuring spherical, aspheric, toric, multifocal, multifocal toric, reverse geometry and keratoconic contact lenses.

    "Many still prefer rigid gas permeable contact lenses for clear, comfortable and consistent vision," said Yang Yang, president, Global Vision Care, Bausch + Lomb. "ASANA offers eye care professionals a catalog of customizable GP lenses designed to fit each patient's unique corneal curves, ensuring a fantastic fit and sharp vision. These GP lenses also complete our custom Specialty Vision Products lens portfolio, offering a comprehensive range of options – from scleral to custom soft, ortho-K and now custom GP lenses."

    ASANA GP lenses are designed to maintain their shape throughout the day, delivering excellent visual acuity. Their rigid material resists protein and fatty deposits, helping to maintain clarity and comfort. Highly durable, they offer strong resistance to breaking and chipping, which can make them a cost-effective option due to less frequent replacement.1-3 For patients with high corneal astigmatism, severe refractive errors, keratoconus, corneal irregularities or post-surgical vision correction needs, gas permeable lenses provide enhanced visual precision to address these more complex vision challenges.1,2

    "Rigid gas permeable corneal contact lenses are an excellent option for certain patients, and having access to consultants to assist with fittings is a critical component of success," said James R. Hoffman, OD, FAAO, Orange Park Eye Center, Orange Park, Florida. "With ASANA, eye care professionals get both, along with fast manufacturing and shipping times, a generous warranty period and an extensive range of lens designs such as spherical, toric, multifocal and more. It's an excellent option, particularly for busy practices."

    ASANA GP lenses are custom made exclusively with Boston® materials, and through the EZ-Exchange Warranty Program, unlimited lens remakes are available for 120 days.* For more information on ASANA GP lens portfolio, visit https://www.bauschsvp.com/lenses/asana/.

    Important Safety Information for Gas Permeable and Customized Soft Contact Lenses

    WARNINGS:

    Patients should be advised of the following warnings pertaining to contact lens wear:

    • Problems with contact lenses and lens care products could result in serious injury to the eye. It is essential that patients follow their eye care practitioner's directions and all labeling instructions for proper use of lenses and lens care products, including the lens case. Eye problems, including corneal ulcers, can develop rapidly and lead to loss of vision.
    • Daily wear lenses are not indicated for overnight wear, and patients should be instructed not to wear lenses while sleeping. Clinical studies have shown that the risk of serious adverse reactions is increased when daily wear lenses are worn overnight.
    • Studies have shown that contact lens wearers who are smokers have a higher incidence of adverse reactions than nonsmokers.
    • If a patient experiences eye discomfort, excessive tearing, vision changes or redness of the eye, the patient should be instructed to immediately remove lenses and promptly contact his or her eyecare practitioner.

    CONTRAINDICATIONS:

    Do not use when any of the following conditions exist:

    • Acute or subacute inflammation or infection of the anterior chamber of the eye.
    • Any eye disease, injury or abnormality, other than keratoconus and PMD that affects the cornea, conjunctiva or eyelids
    • Severe insufficiency of lacrimal secretion (dry eye)
    • Corneal hypoesthesia (reduced sensitivity), if not aphakic
    • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses
    • Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or using contact lens solutions
    • Allergy to any ingredient in a solution, which is to be used to care for contact lenses
    • Any active corneal infection (bacterial, fungal or viral)
    • Red or irritated eyes

    ADVERSE EFFECTS:

    The following problems may occur with the use of contact lenses:

    • Eyes stinging, burning, itching, irritation or other eye pain
    • Comfort is less than when the lens was first placed on the eye
    • Feeling of something in the eye such as a foreign body or scratched area
    • Excessive watering (tearing) of the eye
    • Unusual eye secretions
    • Redness of the eyes
    • Reduced sharpness of vision (poor visual acuity)
    • Blurred vision, rainbows or halos around objects
    • Sensitivity to light (photophobia)
    • Dry eyes 

    About Bausch + Lomb

    Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we've evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we're turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

    *See bauschsvp.com/policies for details.

    References

    1. Lazarus R. Optometrists Network. Guide to hard contact lenses. Accessed July 20, 2025. optometrists.org/general-practice-optometry/optical/guide-to-contact-lenses/guide-to-hard-contact-lenses/.
    2. Wolffsohn JS, Dumbleton K, Huntjens B, et al. CLEAR - Evidence-based contact lens practice. Cont Lens Anterior Eye. 2021;44(2):368-397.
    3. Heiting G. All About Vision. Gas permeable contact lenses (RGP or GP contacts). Accessed July 20, 2025. allaboutvision.com/eyewear/contact-lenses/types/hard-contact-lenses/.

    ©2025 Bausch + Lomb.

    MTB.0473.USA.25

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250908684391/en/

    Media Contact:

    Kristy Marks

    [email protected]

    (908) 927-0683

    Get the next $BLCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    1/5/2026$18.00Outperform → In-line
    Evercore ISI
    12/11/2025$20.00Neutral → Buy
    Citigroup
    12/2/2025$21.00Equal-Weight → Overweight
    Morgan Stanley
    10/1/2025$16.00Neutral
    Goldman
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch + Lomb Launches R&D "Teach-in" Webinar Series

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D "Teach-in" webinar series that will provide deeper insights on the company's differentiated product pipeline, which was unveiled in November 2025. On Monday, March 23, 2026, at 1:30 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hashad, MD, will be joined by members of his leadership team to discuss two glaucoma assets: BL1107, a glaucoma medication under development that would be the first to treat vision loss in addition to lowering intraocular pressure ELIOS™, an

    3/9/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

    Global review highlights increasing prevalence of noninfectious ocular redness due to digital eye strain, dry eye disease, allergies and environmental exposures LUMIFY redness reliever eye drops (brimonidine tartrate 0.025%) are highlighted as a differentiated OTC option due to its highly selective α2 mechanism, with no tachyphylaxis over 29 days and virtually no rebound redness Review also notes a preservative-free formulation of brimonidine tartrate 0.025% showing comparable efficacy, safety and tolerability; Bausch + Lomb introduced LUMIFY Preservative Free Eye Drops in 2025 Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping peop

    2/24/26 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

    Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results Revenue of $1.405 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $58 Million Adjusted EBITDA (non-GAAP)1 of $326 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $330 Million Revenue Grew 10% as Reported and 7% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2024 Full-Year 2025 Financial Results Revenue of $5.101 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $360 Million Adjusted EBITDA (non-GAAP)1 of $858 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1

    2/18/26 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bausch + Lomb Corporation

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 5:23:22 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    EVP and CFO Eldessouky Sam bought $68,520 worth of shares (4,000 units at $17.13) and was granted 4,000 shares, increasing direct ownership by 2% to 407,130 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:34:11 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $251,958 worth of shares (14,700 units at $17.14) and was granted 14,700 shares, increasing direct ownership by 3% to 981,275 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:32:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CFO Eldessouky Sam bought $68,520 worth of shares (4,000 units at $17.13) and was granted 4,000 shares, increasing direct ownership by 2% to 407,130 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:34:11 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $251,958 worth of shares (14,700 units at $17.14) and was granted 14,700 shares, increasing direct ownership by 3% to 981,275 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:32:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Ross Thomas W. Sr. bought $79,556 worth of shares (4,500 units at $17.68) and was granted 4,500 shares, increasing direct ownership by 15% to 69,391 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/4/26 4:18:54 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    SEC Filings

    View All

    SEC Form 10-K filed by Bausch + Lomb Corporation

    10-K - Bausch & Lomb Corp (0001860742) (Filer)

    2/18/26 5:19:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    2/18/26 7:01:45 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    1/2/26 4:10:34 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bausch + Lomb downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Bausch + Lomb from Outperform to In-line and set a new price target of $18.00

    1/5/26 8:46:17 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Citigroup with a new price target

    Citigroup upgraded Bausch + Lomb from Neutral to Buy and set a new price target of $20.00

    12/11/25 8:44:49 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $21.00

    12/2/25 8:17:09 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

    5/21/25 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

    Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

    2/28/24 8:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

    2/21/24 7:00:00 AM ET
    $BLCO
    $EBS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BLCO
    Financials

    Live finance-specific insights

    View All

    Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

    Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results Revenue of $1.405 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $58 Million Adjusted EBITDA (non-GAAP)1 of $326 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $330 Million Revenue Grew 10% as Reported and 7% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2024 Full-Year 2025 Financial Results Revenue of $5.101 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $360 Million Adjusted EBITDA (non-GAAP)1 of $858 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1

    2/18/26 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Feb. 18, 2026   Time: 8:00 a.m. ET   Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392   Pa

    1/20/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Third-Quarter 2025 Results

    Revenue of $1.281 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $28 Million Adjusted EBITDA (non-GAAP)1 of $243 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $243 Million Revenue Grew 7% as Reported and 6% on a Constant Currency1 Basis Compared to the Third Quarter of 2024 Updating Full-Year 2025 Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2025 financial results. "We're delivering on the vision we laid out in 2023, with a base business engine that con

    10/29/25 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch + Lomb Corporation

    SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

    2/14/23 5:14:30 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care